Abstract: Objective :To investigate long-term efficacy of biochemotherapy for metastatic lesionsof renal cell carcinoma. Methods :Sixty-three patients with renal carcinoma who received radicalnephrectomy and had pathologic indications of clear-cell carcinoma were divided into two groups. Thir-ty patients in the treatment group were treated with biochemotherapy, consisting of a regimen of IFN-αand IL-2 plus 5-FU 2 weeks after the radical nephrectomy. The other 33 patients in the control groupreceived no biochemotherapy after the radical operation. Results : The median survival time for patientsin the treatment group was 22 months, which was much longer than the 9 months seen in the controlgroup. The survival curve for the biochemotherapy group was higher than that of the control group (P<0.01).The overall remission rate for patients with metastatic lesions was 63.3%, and the adverse sideeffects ranged from degree 0 to Ⅰ. Conclusion :The survival rate can be increased in patients withclear-cell carcinoma of Stage RobsonⅣB, and the metastatic lesions can partially be relieved. Further-more, the adverse side effects were well-tolerated by all cases. Biochemotherapy as a treatment for re-nal cell carcinoma after radical nephrectomy is an effective method that should be used clinically moreoften,especially for cases of clear-cell carcinoma.